DK4103566T3 - Kondenserede pyrimidinforbindelser som kcc2-modulatorer - Google Patents

Kondenserede pyrimidinforbindelser som kcc2-modulatorer Download PDF

Info

Publication number
DK4103566T3
DK4103566T3 DK21712145.8T DK21712145T DK4103566T3 DK 4103566 T3 DK4103566 T3 DK 4103566T3 DK 21712145 T DK21712145 T DK 21712145T DK 4103566 T3 DK4103566 T3 DK 4103566T3
Authority
DK
Denmark
Prior art keywords
kcc2
modulators
pyrimidine compounds
condensed pyrimidine
condensed
Prior art date
Application number
DK21712145.8T
Other languages
Danish (da)
English (en)
Inventor
Rebecca Elizabeth Jarvis
Roland Werner Bürli
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK4103566T3 publication Critical patent/DK4103566T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DK21712145.8T 2020-03-13 2021-03-12 Kondenserede pyrimidinforbindelser som kcc2-modulatorer DK4103566T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062989104P 2020-03-13 2020-03-13
PCT/EP2021/056393 WO2021180952A1 (en) 2020-03-13 2021-03-12 Fused pyrimidine compounds as kcc2

Publications (1)

Publication Number Publication Date
DK4103566T3 true DK4103566T3 (da) 2023-10-30

Family

ID=74874882

Family Applications (1)

Application Number Title Priority Date Filing Date
DK21712145.8T DK4103566T3 (da) 2020-03-13 2021-03-12 Kondenserede pyrimidinforbindelser som kcc2-modulatorer

Country Status (25)

Country Link
US (1) US12617795B2 (cg-RX-API-DMAC7.html)
EP (1) EP4103566B1 (cg-RX-API-DMAC7.html)
JP (2) JP7793529B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220152319A (cg-RX-API-DMAC7.html)
CN (4) CN119684299A (cg-RX-API-DMAC7.html)
AU (1) AU2021234134B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022018173A2 (cg-RX-API-DMAC7.html)
CA (1) CA3171192A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022002386A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022012884A2 (cg-RX-API-DMAC7.html)
DK (1) DK4103566T3 (cg-RX-API-DMAC7.html)
ES (1) ES2962136T3 (cg-RX-API-DMAC7.html)
FI (1) FI4103566T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20231314T1 (cg-RX-API-DMAC7.html)
HU (1) HUE064037T2 (cg-RX-API-DMAC7.html)
IL (1) IL296265B2 (cg-RX-API-DMAC7.html)
LT (1) LT4103566T (cg-RX-API-DMAC7.html)
MX (1) MX2022011354A (cg-RX-API-DMAC7.html)
PE (1) PE20230106A1 (cg-RX-API-DMAC7.html)
PL (1) PL4103566T3 (cg-RX-API-DMAC7.html)
PT (1) PT4103566T (cg-RX-API-DMAC7.html)
RS (1) RS64823B1 (cg-RX-API-DMAC7.html)
SI (1) SI4103566T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202300384T1 (cg-RX-API-DMAC7.html)
WO (1) WO2021180952A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022407047A1 (en) * 2021-12-08 2024-07-25 Kineta, Inc. Bicyclic heteroarenes and methods of their use
CN117843618A (zh) * 2022-08-29 2024-04-09 北京沐华生物科技有限责任公司 一种ep300/cbp调节剂及其制备方法和用途
CN121241048A (zh) * 2023-04-05 2025-12-30 艾索尼斯治疗公司 Kcc2增强剂及其用途
US20260191874A1 (en) * 2024-03-06 2026-07-09 Ovid Therapeutics Inc. Fused amino pyrimidine compounds for treatment of autism spectrum disorder, obsessive compulsive disorder and tics
WO2025188955A1 (en) * 2024-03-06 2025-09-12 Ovid Therapeutics Inc. Fused amino pyrimidine compounds for treatment of psychosis and psychotic disorders
WO2025188977A1 (en) * 2024-03-06 2025-09-12 Ovid Therapeutics Inc. Fused amino pyrimidine compounds for treatment of addiction and insomnia
WO2025188976A1 (en) * 2024-03-06 2025-09-12 Ovid Therapeutics Inc. Fused amino pyrimidine compounds for treatment of neurodegenerative disorders
US20250281498A1 (en) * 2024-03-06 2025-09-11 Ovid Therapeutics Inc. Fused amino pyrimidine compounds for treatment of synucleinopathies and tdp-43 proteinopathies
WO2025188973A1 (en) * 2024-03-06 2025-09-12 Ovid Therapeutics Inc. Fused amino pyrimidine compounds for treatment of 22q11.2 deletion/duplication syndromes
WO2025188951A1 (en) * 2024-03-06 2025-09-12 Ovid Therapeutics Inc. Fused amino pyrimidine compounds for treatment of seizure disorders
WO2025188953A1 (en) * 2024-03-06 2025-09-12 Ovid Therapeutics Inc. Fused amino pyrimidine compounds for treatment of neuropathic and neuro-inflammatory pain
WO2025188979A1 (en) * 2024-03-06 2025-09-12 Ovid Therapeutics Inc. Fused amino pyrimidine compounds and pridopidine for treatment of huntington's disease
US20260108529A1 (en) * 2024-10-23 2026-04-23 Ovid Therapeutics Inc. Fused amino pyrimidine compounds for treatment of tinnitus, acute sensorineural hearing loss, age-related hearing loss, and meniere's disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3398152B2 (ja) 1993-10-12 2003-04-21 ブリストル‐マイヤーズ・スクイブ・ファーマ・カンパニー 1n−アルキル−n−アリールピリミジンアミンおよびその誘導体
US20090099195A1 (en) * 2007-05-08 2009-04-16 Astrazeneca Ab Therapeutic Compounds 570
RS53382B (sr) 2008-08-20 2014-10-31 Zoetis Llc Jedinjenja pirol [2,3-d]pirimidina
AR079814A1 (es) * 2009-12-31 2012-02-22 Otsuka Pharma Co Ltd Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos
US9340540B2 (en) 2014-02-28 2016-05-17 Nimbus Lakshmi, Inc. TYK2 inhibitors and uses thereof
WO2018217766A1 (en) 2017-05-22 2018-11-29 Whitehead Institute For Biomedical Research Kcc2 expression enhancing compounds and uses thereof
JP7399848B2 (ja) * 2017-09-01 2023-12-18 カドモン コーポレイション,リミティド ライアビリティ カンパニー Rho関連コイルドコイル含有プロテインキナーゼの阻害剤
KR20210050493A (ko) * 2018-05-25 2021-05-07 더 칠드런스 메디칼 센터 코포레이션 척수 손상의 치료 방법

Also Published As

Publication number Publication date
SMT202300384T1 (it) 2024-01-10
CN119735594A (zh) 2025-04-01
EP4103566A1 (en) 2022-12-21
PL4103566T3 (pl) 2024-02-05
JP2023517680A (ja) 2023-04-26
AU2021234134A1 (en) 2022-11-03
JP2025186368A (ja) 2025-12-23
FI4103566T3 (fi) 2023-10-20
PT4103566T (pt) 2023-11-09
HRP20231314T1 (hr) 2024-02-16
IL296265B1 (en) 2025-12-01
LT4103566T (lt) 2023-11-10
ES2962136T3 (es) 2024-03-15
BR112022018173A2 (pt) 2022-10-25
MX2022011354A (es) 2022-11-30
IL296265B2 (en) 2026-04-01
JP7793529B2 (ja) 2026-01-05
US12617795B2 (en) 2026-05-05
AU2021234134B2 (en) 2025-08-21
CA3171192A1 (en) 2021-09-16
HUE064037T2 (hu) 2024-03-28
WO2021180952A9 (en) 2021-12-16
PE20230106A1 (es) 2023-01-25
SI4103566T1 (sl) 2024-04-30
CN115298182A (zh) 2022-11-04
RS64823B1 (sr) 2023-12-29
CN119684299A (zh) 2025-03-25
WO2021180952A1 (en) 2021-09-16
EP4103566B1 (en) 2023-10-04
IL296265A (en) 2022-11-01
CN115298182B (zh) 2025-02-11
KR20220152319A (ko) 2022-11-15
CL2022002386A1 (es) 2023-04-28
US20230151013A1 (en) 2023-05-18
CO2022012884A2 (es) 2022-10-11
CN119684300A (zh) 2025-03-25

Similar Documents

Publication Publication Date Title
DK4021901T3 (da) Substituerede pyridopyrimidinonylforbindelser som er nyttige som t-celleaktivatorer
DK3774791T3 (da) Heterocykliske forbindelser som immunmodulatorer
DK4069691T3 (da) Substituerede tetrahydrofuraner som modulatorer af natriumkanaler
DK4063364T3 (da) Pyrrolotriazinforbindelse fungerende som mnk-inhibitor
DK3873903T3 (da) Substituerede 6-azabenzimidazolforbindelser som hpk1-hæmmere
EP4293027A4 (en) PYRIMIDINE COMPOUNDS WITH AROMATIC RING
DK3625228T3 (da) Pyrimidinderivater som pge2-receptormodulatorer
DK3656769T3 (da) Aryl-phosphor-oxygen-forbindelse som egfr-kinase-inhibitor
EP4164748C0 (en) CYCLOPROPYL-DIHYDROQUINOLINE SULFONAMIDE COMPOUNDS
DK3697785T3 (da) Imidazo-pyridine forbindelser som pad-inhibitorer
EP4165032C0 (en) HETEROALKYL DIHYDROQUINOLINE SULFONAMIDE COMPOUNDS
DK4219492T3 (da) Heterocykliske forbindelser som immunmodulatorer
DK3577110T3 (da) 8-oxetan-3-yl-3,8-diazabicyclo[3.2.1]octan-3-yl-substituerede forbindelser som hiv-inhibitorer
DK3436461T3 (da) Pyrrolotriazinforbindelser som tam-inhibitorer
DK3672965T3 (da) Pyramidinforbindelse som Jak-kinase-inhibitor
DK3822272T3 (da) Kondenseret tri-cyklisk forbindelse som pde3/pde4-dobbeltinhibitor
DK3341367T3 (da) Bicyklisk-fusionerede heteroaryl- eller arylforbindelser som irak4-modulatorer
ME03669B (me) NOVO KONDENZOVANO PIRIMIDINSKO JEDINJENJE ILl NJEGOVA SO
DK3321265T3 (da) 4,6-diamino-pyrido[3,2-d]pyrimidinforbindelser og deres udnyttelse som modulatorer af toll-lignende receptorer
DK3294713T3 (da) Substituerede tetrahydroquinolinonforbindelser som ror-gamma-modulatorer
MX378735B (es) Moduladores de receptores de quimiocina
IL309378A (en) Diacylglyercol kinase modulating compounds
DK3582780T3 (da) Aminopyrimidinforbindelser, der er anvendelige som SSAO-inhibitorer
DK3762368T3 (da) Aminopyrazindiolforbindelser som pi3k-y-inhibitorer
IL310528A (en) Pyrazolopyridinone compounds